CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
Go back to CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab| CytoDyn, Inc. (AMEX: CYDY) | Delayed: 0.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.15 | 52 Week High | $1.57 | |||
| Open | $0.15 | 52 Week Low | $0.61 | |||
| Day High | $0.15 | P/E | N/A | |||
| Day Low | $0.15 | EPS | $0.00 | |||
| Volume | 648,615 | |||||
